pharmaphorum

OCTOBER 19, 2020

The FDA’s approval covers use of Venclexta (venetoclax) in combination with azacytidine, or decitabine, or low-dose cytarabine (LDAC) for newly diagnosed AML in adults 75 years or older, or who have comorbidities preventing intensive induction chemotherapy. months compared with 4.1 months for those treated with LDAC alone.

Adverse Reactions 59

Adverse Reactions Chemotherapy Labelling 59

pharmaphorum

APRIL 14, 2021

Trodelvy (sacituzumab govitecan) has been approved for locally advanced or metastatic urothelial cancer, following a platinum-containing chemotherapy and PD-1/PD-L1 inhibitor immunotherapy. Adverse reactions leading to treatment discontinuation occurred in 10% of those receiving Trodelvy, with 4% discontinuing treatment due to neutropenia.

Adverse Reactions 52

Adverse Reactions Chemotherapy 52

pharmaphorum

APRIL 1, 2021

The FDA has approved Sanofi’s Sarclisa (isatuximab) in combination with a new chemotherapy regimen for advanced multiple myeloma, building on a first approval last year. The median progression free survival (PFS) for Sarclisa combination therapy was not reached at the time of the pre-planned interim analysis, the company said.

Adverse Reactions 59

Adverse Reactions Labelling Chemotherapy 59

Pharmaceutical Technology

MAY 22, 2023

As a non-chemotherapy, single-agent treatment for DLBCL patients, we hope that Epkinly can effectively treat this aggressive cancer type and can be used for patient care quickly and in an off-the-shelf form for physicians. The FDA approval of Epkinly represents a new treatment mechanism of action for third-line DLBCL patients. “As

Adverse Reactions 52

Adverse Reactions Chemotherapy 52

Pharmaceutical Technology

MARCH 17, 2023

According to the findings, participants treated with Tafinlar + Mekinist had a 47% overall response rate (ORR) compared to those who received chemotherapy.

Adverse Reactions 52

Adverse Reactions Chemotherapy 52

PharmaShots

JUNE 6, 2023

Shots: The P-III study (TROPiCS-02) evaluating Trodelvy vs CT in a ratio (1:1) in 543 patients with HR+/HER2- metastatic breast cancer who progressed on endocrine-based therapies and 2 chemotherapies In the exploratory analysis, improvement in m-OS benefit (14.5 vs 11.2mos.), PFS rates at 6/12/18mos. vs 29.4%)/ (21.7% vs 8.4%)/ (14.4%

Adverse Reactions 40

Adverse Reactions Chemotherapy 40

Pharmaceutical Technology

JANUARY 12, 2023

It has been approved to treat NSCLC patients with EGFR Exon20 insertion mutations, whose disease has advanced on or after they received platinum-based chemotherapy. Rash, decreased appetite, paronychia, and diarrhoea are the most common adverse reactions (TRAEs) related to the treatment.

Adverse Reactions 52

Adverse Reactions Chemotherapy 52

pharmaphorum

JANUARY 26, 2022

It covers three phase 3 trials involving subjects with myelodysplastic syndrome (MDS) and acute myeloid leukaemia (AML), as well as ‘unfit’ AML patients who are unable to be treated with intensive treatment like high-dose chemotherapy.

Adverse Reactions 40

Adverse Reactions Chemotherapy Immunity Immunization 40

European Pharmaceutical Review

DECEMBER 27, 2023

Bridging therapy has been shown to correlate with an inferior response to CAR T-cell therapy due to both progression of the chemotherapy-refractory malignant disease during the manufacturing period and increased toxicity. After this incident CAR-related toxicity scales and guidelines were established to prevent adverse reactions.

Adverse Reactions 104

Adverse Reactions Immunity Immunization Medical Schools 104

Express Pharma

JUNE 18, 2024

This is the first Phase 3 trial to statistically evaluate an anti-PD-1 immunotherapy plus chemotherapy combination in patients with pMMR and dMMR tumours as two independent cohorts,” said Dr Ramez N. Early identification and management of immune-mediated adverse reactions are essential to ensure safe use of KEYTRUDA.

Chemotherapy 59

Chemotherapy Adverse Reactions Immunity Immunization 59

LifeProNow

APRIL 30, 2023

Adverse Reactions (ARs): In the data from the four randomized placebo-controlled trials, the most common ARs (≥ 10%) that occurred more frequently (≥ 2% over placebo) in XTANDI-treated patients were asthenia/fatigue, back pain, hot flush, constipation, arthralgia, decreased appetite, diarrhea, and hypertension.

Adverse Reactions 130

Adverse Reactions Chemotherapy Diabetes 130

European Pharmaceutical Review

NOVEMBER 24, 2022

s Libtayo ® (cemiplimab) for adults with recurrent or metastatic cervical cancer and disease progression while on or after platinum-based chemotherapy. “Libtayo ® was the first programmed cell death protein (PD)-1 inhibitor to demonstrate significant improvements in survival compared to chemotherapy in a Phase III trial.

Chemotherapy 98

Chemotherapy Immunity Immunization Adverse Reactions 98

The Thyroid Pharmacist

JULY 8, 2022

It’s important to note that selenium may also interact with other supplements and medications, such as cholesterol-lowering statin drugs, antacids, chemotherapy drugs, corticosteroids, niacin, and even birth control pills. At high enough levels, selenium can cause death (reports of this level of toxicity exist, but are extremely rare). (58,

Dosage 59

Dosage Immunity Immunization Diabetes 59

Pharmaceutical Technology

NOVEMBER 23, 2022

Libtayo is also indicated for treating progression of the disease on or following platinum-based chemotherapy. The trial enrolled 608 subjects in 14 countries, regardless of their PD-L1 expression status or histology and assessed Libtayo versus a chemotherapy of investigator's choice.

Adverse Reactions 52

Adverse Reactions Chemotherapy Immunity Immunization 52

RX Note

FEBRUARY 23, 2023

G6PD Deficiency - Explaining G6PD Deficiency Ramadan - Medications during Ramadan fasting Adverse Drug Reactions Adverse Drug Reactions - All adverse reactions are adverse drug event Pharmacovigilance - To detect unreported ADRs Drug Allergy - Management vary based on the signs and symptoms Medicine-induced Discolouration - Red?

HIV Treatment and Prevention Agents 58

HIV Treatment and Prevention Agents Community Pharmacies Labelling Chemotherapy 58

The Thyroid Pharmacist

SEPTEMBER 1, 2023

They include anesthetics, antacids, anti-anxiety medications, antibiotics, antidepressants, antifungals, cholesterol-lowering medications, anti-malarial medications, chemotherapy, appetite suppressants, arthritis medications, psychotropics, and steroids. Who is Likely to Have an Adverse Reaction to Fluoride, and What are the Symptoms?

Adverse Reactions 116

Adverse Reactions Compounding Chemotherapy Labelling 116

LifeProNow

MAY 8, 2023

The standard therapy for these patients consists of intensive salvage immunochemotherapy followed by high-dose chemotherapy and HSCT for those whose disease responds to the salvage therapy and are eligible for transplant.

Chemotherapy 130

Chemotherapy Adverse Reactions 130

LifeProNow

APRIL 19, 2023

Vaccination with live virus vaccines is not recommended for at least 6 weeks prior to the start of lymphodepleting chemotherapy, during ABECMA treatment, and until immune recovery following treatment with ABECMA. The safety of immunization with live viral vaccines during or after ABECMA treatment has not been studied.

Adverse Reactions 100

Adverse Reactions Vaccines Immunity Immunization 100

Express Pharma

DECEMBER 30, 2024

The most common adverse reactions (10 per cent) were fatigue, musculoskeletal pain, pruritus, rash, and cough. ORR was 24 per cent (95 per cent CI: 19,30) in the subcutaneous nivolumab and hyaluronidase-nvhy arm and 18 per cent (95 per cent CI: 14, 24) in the intravenous nivolumab arm.

Adverse Reactions 52

Adverse Reactions Dosage Chemotherapy Labelling 52